Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

Authors :: Lee, Hun Ju
Ramchandren, Rod
Friedman, Judah
Melear, Jason
Flinn, Ian W.
Burke, John M.
Linhares, Yuliya
Gonzales, Paul
Peterson, Matthew
Raval, Mihir
Chintapatla, Rangaswamy
Feldman, Tatyana A.
Yimer, Habte
Islas-Ohlmayer, Miguel
Patel, Ameet
Metheny, Leland
Dean, Asad
Rana, Vishal
Gandhi, Mitul D.
Renshaw, John
Ho, Linda
Fanale, Michelle A.
Guo, Wenchuan
Yasenchak, Christopher A.
Source :: Blood; January 2025, Vol. 145 Issue: 3 p290-299, 10p
Publication Year :: 2025
Abstract: •With a median follow-up of 24.2 months, the 2-year progression-free survival of patients treated with AN+AD was 88%.•AN+AD led to an 88% CR rate and favorable safety profile, notable for the absence of febrile neutropenia.

Full Text Access

Tools